I recently conducted an interview with Dr. Joanne Kurtzberg of Duke. You can see Part 1 of the interview here. Today in Part 2, I asked Dr. Kurtzberg some broader questions about the stem cell field. 1. How concerned are you about non-compliant stem cell interventions here in the US as well as stem cell […]
Joanne Kurtzberg interview, Part 2: clinics & stem cell field future Read More »
Dr. Joanne Kurtzberg is a stem cell pioneer and has advanced the development of innovative stem cell therapies including those based on umbilical cord blood. She is a faculty member at Duke where she conducts her clinical research. I recently interviewed Dr. Kurtzberg and below is Part 1 of 2 of the interview. Part 2,
Stem Cell Pioneer Joanne Kurtzberg interview, Part 1 Read More »
The Parent’s Guide to Cord Blood Foundation recently announced that Cryo-Cell and its long-time partner, a Duke pediatric cell therapy team, have made a key change. They will begin offering infusions of unrelated, unproven cord blood to pediatric patients with cerebral palsy (CP). These are called donor infusions. Up until now, they had mainly focused
My lab is focused in part on chromatin states in stem cells and cancer including heterochromatin. In fact, my lab’s website is chromatin.com. Heterochromatin is dense, often inactive chromatin. By H&E staining and electron microscopy, heterochromatin looks dark compared to the rest of the nucleus, largely composed of euchromatin. Toward the end of my postdoc
Weekly reads: heterochromatin, H3.3, Mesoblast bump Read More »
Almost two years ago I publicly called on the FDA to freeze the unproven cord cell expanded access program (EAP) at the Duke Autism Center. Duke has been infusing kids with autism spectrum disorder (ASD) with unproven cord cells and requiring large payments for this. The cost was as much as $15,000. A halt and a
Why did Duke autism team halt its troubling pay-for-play program? Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
Viacord is one of the most well known firms in the for-profit cord blood banking industry. Today’s post is a review of the firm. I see concrete reasons for concern. What is Viacord? | Dubious autism claims | Viacord cost | Overall Review | References What is Viacord? As a cord blood banking firm, Viacord freezes
Review of cord banker Viacord: dubious autism claims & other concerns Read More »
I’ve been concerned that the journal Stem Cells Translational Medicine has been publishing some iffy papers from unproven stem cell clinics recently including from a Panama stem cell clinic called the Stem Cell Institute. Back in 2019, I took the unusual step of raising the question of whether a Stem Cells Translational Medicine paper from Neil Riordan,
Questions remain after Stem Cells Translational Medicine retracts clinic pub Read More »
When I first learned about the multi-$10 million cord cell clinic deal between Duke and Cryo-Cell I couldn’t believe what I was reading. Duke’s involved in this? The problem: marketing unproven cells for kids Yes, this wasn’t some stem cell clinic operating out of a strip mall seeking to make big money off of injecting
Vice tackles dicey Cryo-Cell Duke mega-million peds clinic plan Read More »
I recently found concerning SEC filings from the biotech Cryo-Cell about a deal it has with a Duke team for infusions of children with unproven umbilical cord cells. This turns out to be a $58 million deal. It relates in a major way to a Duke compassionate use or expanded access program (EAP) that already had raised
FDA should freeze Duke EAP & probe $58 million Cryo-Cell deal linked to it Read More »